Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

• Published in: Journal of the American Society of Nephrology Vol. 32; no. 9; pp. 2352 - 2361
• Main Authors: Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefánsson, Bergur V., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J.L.
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.09.2021
• Subjects: Aged; Benzhydryl Compounds - therapeutic use; Cardiovascular Diseases - epidemiology; Clinical Research; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Nephropathies - diagnosis; Diabetic Nephropathies - epidemiology; Female; Glomerular Filtration Rate; Glucosides - therapeutic use; Humans; Male; Middle Aged; Renal Insufficiency, Chronic - diagnosis; Renal Insufficiency, Chronic - epidemiology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; stage 4 CKD; chronic kidney disease; SGLT2 inhibitor; dapagliflozin

Significance Statement Relatively little is known about the relative safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with advanced (stage 4) CKD. The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial enrolled patients wit...